Non-hormonal management of vasomotor symptoms

References

• Avis NE, Colvin A, Bromberger JT, et al. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women’s Health Across the Nation. Menopause 2009;16:860–9
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012 Oct 9; 345:e6409
   PubMed Web of Science ®Google Scholar
• Wolff EF, He Y, Black DM, et al. Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Fertil Steril 2013;99:1385–91
   PubMed Web of Science ®Google Scholar
• Tong IL. Nonpharmacological treatment of postmenopausal symptoms. The Obstetrician and Gynaecologist 2013;15:19–25
   Google Scholar
• Freedman RR. Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology 2007;26:573–9
   Google Scholar
• Kronenberg F, Cote LJ, Linkie DM, Dyrenfurth I, Downey JA. Menopausal hot flashes: thermoregulatory, cardiovascular, and circulating catecholamine and LH changes. Maturitas 1984;6:31–43
   PubMed Web of Science ®Google Scholar
• Casper RF, Yen SSC. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol 1985;22: 293–312
   PubMed Web of Science ®Google Scholar
• Stearns V, Ullmer L, Lopez J, Smith Y, Isaacs C, Hayes DF. Hot flushes. Lancet 2002;360:1851–61
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Barton DL, Adjei AA, Loprinzi C. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207–18
   PubMed Web of Science ®Google Scholar
• Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354–8
   PubMed Web of Science ®Google Scholar
• Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70:332–7
   PubMed Web of Science ®Google Scholar
• Freedman RR. Core body temperature during menopausal hot flushes. Fertil Steril 1996;65:1141–4
   PubMed Web of Science ®Google Scholar
• Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999;181:66–70
   PubMed Web of Science ®Google Scholar
• Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertil Steril 2002;77:487–90
   PubMed Web of Science ®Google Scholar
• Brockie JA, Barlow DH, Rees MCP. Menopausal flush symptomatology and sustained reflex vasoconstriction. Hum Reprod 1991;6:472–4
   PubMed Web of Science ®Google Scholar
• Ginsburg J, Hardiman P, O’Reilly B. Peripheral blood flow in menopausal women who have hot flushes and in those who do not. Br Med J 1989;298:1488–90
   PubMed Web of Science ®Google Scholar
• Sassarini J, Fox H, Ferrell W, Sattar N, Lumsden MA. Vascular function and cardiovascular risk factors in women with severe flushing. Clin Endocrinol 2011;74:97–103
   PubMed Web of Science ®Google Scholar
• Brück K, Zeisberger E. Adaptive changes in thermoregulation and their neuropharmacological basis. Pharmacol Therapeut 1987;35:163–215
   PubMed Web of Science ®Google Scholar
• Delaunay L, Bonnet F, Liu N, Beydon L, Catoire P, Sessler D. Clonidine comparably decreases the thermoregulatory thresholds for vasoconstriction and shivering in humans. Anesthesiology 1993;79:470–4
   PubMed Web of Science ®Google Scholar
• Delaunay L, Herail T, Sessler DI, Lienhart A, Bonnet F. Clonidine increases the sweating threshold, but does not reduce the gain of sweating. Anesth Analg 1996;83:844–8
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057–71
   PubMed Web of Science ®Google Scholar
• Ginsburg J, O’Reilly B, Swinhoe J. Effect of oral clonidine on human cardiovascular responsiveness: a possible explanation of the therapeutic action of the drug in menopausal flushing and migraine. Br J Obstet Gynaecol 1985;92:1169–75
   PubMedGoogle Scholar
• Sassarini J, Fox H, Ferrell W, Sattar N, Lumsden MA. Hot flushes, vascular reactivity and the role of the alpha-adrenergic system. Climacteric 2012;15:332–8
   PubMed Web of Science ®Google Scholar
• Berendsen HHG. Hot flushes and serotonin. Menopause Int 2002;8:30–4
   Google Scholar
• Fink G, Sumner BEH. Oestrogen and mental state. Nature 1996;383:306
   PubMed Web of Science ®Google Scholar
• Blum I, Vered Y, Lifshitz A, et al. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. Isr J Med Sci 1996;32:1158–62
   PubMedGoogle Scholar
• Kugaya A, Epperson CN, Zoghbi S, et al. Increase in prefrontal cortex serotonin2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160:1522–4
   PubMed Web of Science ®Google Scholar
• Sumner BEH, Grant KE, Rosie R, Hegele-Hartung C, Fritzemeier KH, Fink G. Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine2A receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Molec Brain Res 1999;73:119–28
   PubMedGoogle Scholar
• Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17–22
   PubMed Web of Science ®Google Scholar
• Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23:6919–30
   PubMed Web of Science ®Google Scholar
• Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes a randomized controlled trial. JAMA 2003;289:2827–34
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63
   PubMed Web of Science ®Google Scholar
• Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161–6
   PubMed Web of Science ®Google Scholar
• Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients – a double-blind, randomised study. Ann Oncol 2007;18:689–93
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan JA, Perez E, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20: 1578–83
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18–26
   PubMed Web of Science ®Google Scholar
• Deecher DC, Alfinito PD, Leventhal L. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomised rodent models. Endocrinology 2007;148:1376–83
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine GD, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77–87
   PubMed Web of Science ®Google Scholar
• Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172e1–10
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, OBach RS, Greenblatt DG. Apparent mechanism-based inhibition of human cyp2d6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Distribution 2003;31:289–93
   PubMed Web of Science ®Google Scholar
• Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010 Feb 8;340:c693
   Google Scholar
• In brief: Tamoxifen and SSRI interaction. Med Lett Drugs Therapeut 2009;51(1314a):45–6
   Google Scholar
• Lash TL, Cronin-Fenton D, Ahern TP, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 2010;49:305–12
   PubMed Web of Science ®Google Scholar
• Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688–97
   PubMed Web of Science ®Google Scholar
• Guttuso JT. Gabapentin’s effects on hot flashes and hypothermia. Neurology 2000;54:2161–3
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818–24
   PubMed Web of Science ®Google Scholar
• Guttuso JT, Kurlan R, McDermott P, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomised controlled trial. Obstet Gynecol 2003;101:337–45
   PubMed Web of Science ®Google Scholar
• Reddy SY, Warner H, Guttuso JT, et al. Gabapentin, estrogen, and placebo for treating hot flushes: A randomized controlled trial. Obstet Gynecol 2006;108:41–8
   PubMed Web of Science ®Google Scholar
• http://www.biospace.com/News/fda-panel-rejects-depomed-inc-menopause-treatment/289443/Source = TopBreaking
   Google Scholar
• Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16:495–500
   PubMed Web of Science ®Google Scholar
• Wong VCK, Lim CED, Luo X, Wong WSF. Current alternative and complementary therapies used in menopause. Gynecol Endocrinol 2009;25:166–74
   PubMed Web of Science ®Google Scholar
• Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Systematic Rev 2007(4)
   Web of Science ®Google Scholar
• Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol – a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577–84
   PubMed Web of Science ®Google Scholar
• Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin H. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005;105:1074–83
   PubMed Web of Science ®Google Scholar
• Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2005;145:869–79
   Web of Science ®Google Scholar
• Davis VL, Jayo MJ, Ho A, et al. Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. Cancer Res 2008;68:8377–83
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009;16:72–84
   PubMed Web of Science ®Google Scholar
• Lee MS, Shin B-C, Ernst E. Acupuncture for treating menopausal hot flushes: a systematic review. Climacteric 2009;12: 16–25
   PubMed Web of Science ®Google Scholar
• Whiteman MK, Staropoli CA, Benedict JC, Borgeest C, Flaws JA. Risk factors for hot flashes in midlife women. J Womens Health (Larchmt) 2003;12:459–72
   PubMed Web of Science ®Google Scholar
• Thurston RC, Sowers MR, Sternfeld B, et al. Gains in body fat and vasomotor symptom reporting over the menopausal transition: the Study of Women’s Health Across the Nation. Am J Epidemiol 2009;170:766–74
   PubMed Web of Science ®Google Scholar
• Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Jerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264–72
   PubMed Web of Science ®Google Scholar
• Daley A, Stokes-Lampard H, Mutrie N, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Systematic Rev 2007 Oct 17;(4):CD006108
   Google Scholar
• Hendy MS, Cockrill B, Sherwood Burge P. The effects of naloxone infusion and stellate ganglion blockade on hot flushes in the human male. Maturitas 1985;7:169–74
   PubMed Web of Science ®Google Scholar
• Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol 2008;9:523–32
   PubMed Web of Science ®Google Scholar
• Lipov EG, Joshi JR, Xie H, Slavin KV. Updated findings on the effects of stellate-ganglion block on hot flushes and night awakenings. Lancet Oncol 2008;9:819–20
   PubMed Web of Science ®Google Scholar
• Haest K, Kumar A, Van Calster B, et al. Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Ann Oncol 2012; 23:1449–54
   PubMed Web of Science ®Google Scholar
• Liu Z YZ, Zhu M, Huo J. Estrogenicity of black cohosh (Cimicifuga racemosa) and its effect on estrogen receptor level in human breast cancer MCF-7 cells. Wei Sheng Yan Jiu 2001; 30:77–80
   PubMedGoogle Scholar